Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to help breast cancer patients stick with treatment by easing pain

NCT ID NCT07409948

Symptom relief Sponsor: Addis Ababa University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a program called AIMSS-CARE for breast cancer patients who have joint and muscle pain from their hormone therapy. The program includes exercise, education, symptom tracking, and follow-up. Eighty-eight patients in Ethiopia will be randomly assigned to the program or usual care to see if it reduces pain and helps them stay on treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multicomponent program (exercise, education, symptom monitoring, follow-up)
What this could lead to
If it works, this could offer a practical way to reduce pain and help patients stay on their cancer treatment.
What could go wrong
This is a small, early-stage study (88 people) in one hospital, so results may not apply broadly. The program is adapted from China and may not work the same in Ethiopia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathologically confirmed hormone receptor-positive (HR+) breast cancer. 2. Aged 18 years or older. 3. Currently receiving aromatase inhibitor therapy (e.g., anastrozole, letrozole, or exemestane) for at least 2 months. 4. Experiencing aromatase inhibitor-induced musculoskeletal symptoms, defined as a worst joint pain score ≥ 2/10 on the Brief Pain Inventory (BPI) during the past 7 days. 5. Capable of understanding the study and willing to sign informed consent. Exclusion Criteria: 1. History of fracture or major surgery within the past 6 months. 2. Patients diagnosed with arthritis (e.g., rheumatoid arthritis). 3. Patients diagnosed with osteoporosis according to WHO criteria (T-score -2.5). 4. Recurrent or metastatic breast cancer, or receipt of chemotherapy or radiotherapy during the study period. 5. Presence of other primary malignancies. 6. Patients with severe heart, brain, liver, or kidney dysfunction, or infectious diseases. 7. Patients with severe mental, cognitive, or behavioral disorders that hinder understanding or participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthralgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arthralgia breast cancer breast neoplasm Fatigue Motor Activity Musculoskeletal Pain musculoskeletal system disorder myalgic encephalomeyelitis/chronic fatigue syndrome Pain Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthralgia Breast neoplasms Fatigue syndrome, chronic Musculoskeletal diseases Musculoskeletal pain Pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.